C. Sire

发表

PET-based prognostic survival model after radiotherapy for head and neck cancer

John O. Prior, J. Bourhis, O. Acosta, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC).

G. Calais, J. Bourhis, C. Sire, 2004, Seminars in oncology.

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.

J. Machiels, C. Sire, S. Temam, 2011 .

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.

V. Grégoire, G. Calais, J. Bourhis, 2012, The Lancet. Oncology.

PPA_A_246757 859..868

G. Calais, M. Bollet, C. Sire, 2020 .

Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer

G. Calais, M. Bollet, C. Sire, 2020, Patient preference and adherence.

Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma.

G. Calais, C. Sire, J. Tortochaux, 1999, Journal of the National Cancer Institute.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy].

G. Calais, C. Sire, J. Tortochaux, 2000, Bulletin du cancer.

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.

J. Bourhis, J. Machiels, C. Sire, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.

G. Calais, E. Babin, E. Blot, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial.

G. Calais, J. Bourhis, C. Sire, 2004, International journal of radiation oncology, biology, physics.

Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

G. Calais, S. Faivre, C. Sire, 2009, Journal of the National Cancer Institute.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

J. Bourhis, C. Sire, A. Aupérin, 2021, The Lancet. Oncology.

Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma. Results of the 94.01 randomized study from the french group of radiation oncology for head and neck cancer (Gortec)

G. Calais, C. Sire, J. Tortochaux, 1998 .

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

J. Prevost, C. Sire, X. Sun, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.

V. Grégoire, G. Calais, J. Bourhis, 2017, Oral oncology.

Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.

G. Calais, C. Sire, P. Garaud, 2016, Journal of the National Cancer Institute.

A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.

C. Sire, D. Cupissol, S. Thézénas, 2020, The American journal of clinical nutrition.

Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.

G. Calais, C. Sire, P. Garaud, 2020, European journal of cancer.

Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study.

G. Calais, C. Sire, P. Garaud, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study.

G. Calais, C. Sire, D. de Raucourt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.

G. Calais, F. Denis, C. Sire, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5500 ORAL Induction chemotherapy for larynx preservation. Updated results of the GORTEC 2000–01 randomized trial comparing docetaxel + cisplatinum + fluorouracil (TPF) versus cisplatinum + fluorouracil (PF)

G. Calais, S. Guérif, C. Sire, 2007 .

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

J. Bourhis, E. Babin, C. Borel, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).

C. Sire, P. Fournel, Y. Tao, 2022, European journal of cancer.

Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).

J. Bourhis, J. Thariat, C. Sire, 2020, European journal of cancer.

Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.

J. Bourhis, C. Sire, P. Blanchard, 2017, International journal of radiation oncology, biology, physics.

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

J. Bourhis, C. Sire, A. Aupérin, 2018 .

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

C. Borel, J. Thariat, C. Sire, 2021, Annals of Oncology.

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.

N. Magné, B. Chauffert, F. Clatot, 2023, European journal of cancer.

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

N. Magné, B. Chauffert, J. Bourhis, 2020, The Lancet. Oncology.

Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.

Fabrice Denis, Gilles Calais, G. Calais, 2003, International journal of radiation oncology, biology, physics.

Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

G. Calais, C. Sire, J. Tortochaux, 1999, Journal of the National Cancer Institute.

LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial

J. Bourhis, J. Prevost, C. Sire, 2020, Annals of Oncology.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial.

J. Bourhis, E. Babin, P. Maingon, 2017 .

1050PDThe ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit

E. Blot, C. Sire, X. Sun, 2017 .

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

J. Bourhis, J. Prevost, C. Sire, 2018 .

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

C. Sire, A. Aupérin, O. Capitain, 2019, Journal of Clinical Oncology.

Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma. final results of the 94-01 GORTEC randomized study

G. Calais, C. Sire, J. Tortochaux, 2001 .

Late toxicity results of randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma (GORTEC 94-01)

G. Calais, F. Denis, C. Sire, 2001 .

Accelerated versus Conventional Radiotherapy with Concomitant Chemotherapy in Locally Advanced Head and Neck Carcinomas: Results of a Phase III Randomized Trial

V. Grégoire, G. Calais, J. Bourhis, 2008 .

Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

J. Bourhis, F. Clatot, C. Sire, 2019, Annals of Oncology.

Absent benefit of accelerated concomitant chemoradiotherapy – Authors' reply

J. Bourhis, C. Sire, P. Blanchard, 2012 .

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET-based prognostic survival model after radiotherapy for head and neck cancer

John O. Prior, J. Bourhis, O. Acosta, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01.

J. Bourhis, C. Sire, J. Tortochaux, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of GORTEC 2000-01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation.

G. Calais, C. Sire, P. Garaud, 2015 .